JAK inhibitor success in steroid-refractory GVHD

Ruxolitinib treatment in patients with grade II to IV glucocorticoid-refractory acute GVHD results in a significantly higher overall response than control therapies, an international phase 3 study shows. The positive results represent a major advance in managing the difficult-to-treat sequelae of allogeneic stem cell transplantation, according to the study investigators. The REACH2 trial comprised 309 ...

Already a member?

Login to keep reading.

© 2021 the limbic